chrX-139530772-G-A
Variant summary
Our verdict is Benign. Variant got -8 ACMG points: 0P and 8B. BA1
This summary comes from the ClinGen Evidence Repository: The c.8G>A (p.Arg3His) variant is reported at an MAF of 0.001469 (28/19065 alleles) in the African/African American population in gnomAD v2.1.1 with 8 hemizygotes, meeting BA1 criteria of MAF > 0.0000556. gnomAD v3.1.1 reports 13 hemizygotes. REVEL score does not meet thresholds for PP3 or BP4. In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the Coagulation Factor Deficiency Variant Curation Expert Panel for F9: BA1. LINK:https://erepo.genome.network/evrepo/ui/classification/CA10529706/MONDO:0010604/080
Frequency
Consequence
NM_000133.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -8 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
F9 | NM_000133.4 | c.8G>A | p.Arg3His | missense_variant | 1/8 | ENST00000218099.7 | NP_000124.1 | |
F9 | NM_001313913.2 | c.8G>A | p.Arg3His | missense_variant | 1/7 | NP_001300842.1 | ||
F9 | XM_005262397.5 | c.8G>A | p.Arg3His | missense_variant | 1/7 | XP_005262454.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
F9 | ENST00000218099.7 | c.8G>A | p.Arg3His | missense_variant | 1/8 | 1 | NM_000133.4 | ENSP00000218099 | P1 | |
F9 | ENST00000394090.2 | c.8G>A | p.Arg3His | missense_variant | 1/7 | 1 | ENSP00000377650 | |||
F9 | ENST00000479617.2 | n.15G>A | non_coding_transcript_exon_variant | 1/4 | 5 |
Frequencies
GnomAD3 genomes AF: 0.000383 AC: 43AN: 112309Hom.: 0 Cov.: 24 AF XY: 0.000377 AC XY: 13AN XY: 34477
GnomAD3 exomes AF: 0.000240 AC: 44AN: 183043Hom.: 0 AF XY: 0.000222 AC XY: 15AN XY: 67651
GnomAD4 exome AF: 0.000129 AC: 141AN: 1095851Hom.: 2 Cov.: 29 AF XY: 0.000127 AC XY: 46AN XY: 361391
GnomAD4 genome AF: 0.000392 AC: 44AN: 112363Hom.: 0 Cov.: 24 AF XY: 0.000376 AC XY: 13AN XY: 34541
ClinVar
Submissions by phenotype
Hereditary factor IX deficiency disease Benign:2
Likely benign, no assertion criteria provided | clinical testing | Natera, Inc. | Oct 31, 2019 | - - |
Benign, reviewed by expert panel | curation | ClinGen Coagulation Factor Deficiency Variant Curation Expert Panel, Clingen | Feb 09, 2024 | The c.8G>A (p.Arg3His) variant is reported at an MAF of 0.001469 (28/19065 alleles) in the African/African American population in gnomAD v2.1.1 with 8 hemizygotes, meeting BA1 criteria of MAF > 0.0000556. gnomAD v3.1.1 reports 13 hemizygotes. REVEL score does not meet thresholds for PP3 or BP4. In summary, this variant meets criteria to be classified as benign. ACMG/AMP criteria applied, as specified by the Coagulation Factor Deficiency Variant Curation Expert Panel for F9: BA1. - |
not specified Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | May 12, 2022 | Variant summary: F9 c.8G>A (p.Arg3His) results in a non-conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 0.00024 in 183043 control chromosomes including 15 hemizygous males. This frequency is not significantly higher than estimated for a pathogenic variant in F9 causing Factor IX Deficiency (Hemophilia B) (0.00024 vs 0.0065), allowing no conclusion about variant significance. To our knowledge, no penetrant association of c.8G>A in individuals affected with Factor IX Deficiency (Hemophilia B) and no experimental evidence demonstrating its impact on protein function have been reported. Four clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation and a majority consensus as benign/likely benign. Based on the evidence outlined above, the variant was classified as likely benign. - |
F9-related disorder Benign:1
Likely benign, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Mar 27, 2023 | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). - |
Hereditary factor IX deficiency disease;C2749016:Thrombophilia, X-linked, due to factor 9 defect Benign:1
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 29, 2024 | - - |
not provided Benign:1
Likely benign, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Mar 08, 2021 | - - |
Hereditary factor IX deficiency disease;C2749016:Thrombophilia, X-linked, due to factor 9 defect;C5393318:Warfarin sensitivity, X-linked Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Apr 29, 2022 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at